October 30, 2018
JCR Pharmaceuticals announced on October 29 that it has initiated development of its regenerative medicine product Temcell HS Injection, containing allogeneic bone marrow-derived mesenchymal stem cells, for an additional indication of epidermolysis bullosa. Epidermolysis bullosa is a genetic disease in...read more